Aaliya Burza, MD
Pulmonary Disease · Brooklyn, NYNPI 1477700425
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (46.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Lilly USA, LLC at 35.2% of the total.
Across 57 payments — averaging $97.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Johnson & Johnson$2K
- Medical Device Business Services, Inc.$1K
- AbbVie$151
- AstraZeneca$117
- Insmed, Inc.$108
- plus $409 from 12 others
Across 8 payments — averaging $47,292 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$378K
What the payments were for
- Consulting fees$1,95035%
- Travel & lodging$2,59547%
- Food & beverage$98418%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 1 | $1,950 |
| Johnson & Johnson(2 entities) | 10 | $1,785 |
| Medical Device Business Services, Inc. | 6 | $1,026 |
| AbbVie(2 entities) | 9 | $151 |
| AstraZeneca | 6 | $117 |
| Insmed, Inc. | 6 | $108 |
| United Therapeutics Corporation | 2 | $88 |
| Amgen | 3 | $68 |
| Boehringer Ingelheim | 3 | $55 |
| Grifols USA, LLC | 2 | $43 |
| GSK | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Verona Pharma, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Kerecis Limited | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$1,668
- MONARCH$926
How this compares
$5,545 in reported general payments places this provider in the 75th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 33 | $419,335 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 106 | $152,055 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $62,042 |
| Fasenra PenBenralizumab | 11 | $58,173 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 87 | $41,054 |
| Spiriva RespimatTiotropium Bromide | 32 | $40,414 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $24,182 |
| Incruse ElliptaUmeclidinium Bromide | 46 | $16,885 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $15,199 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $12,982 |
| Pirfenidone | 11 | $8,372 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 143 | $7,325 |
| Spiriva HandihalerTiotropium Bromide | 13 | $6,876 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 14 | $4,760 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $3,345 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $55 | $483,93088 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta | $33 | $228,274285 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $117 | $75,02464 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Brooklyn
- Ali El AtatBrooklyn$482K
- Sunil MehraBrooklyn$388K
- Xiaojun YanBrooklyn$249K
- Boris SagalovichBrooklyn$212K
- Chaim BernsteinBrooklyn$186K
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.